fda stopping semaglutide approves obesity drug that helped people cut weight 15% US FDA to hold off

For 503A pharmacies, the FDA confirmed a narrow enforcement safe harbor: the agency does not currently intend to take action against pharmacies that compound an essentially-a-copy GLP-1 product, provided they fill no more than four prescriptions of that preparation per calendar month

Thats why there are many products in the market

Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment

This is especially important to know if you're on a GLP-1 medication, since semaglutide and tirzepatide can also cause constipation

We found that exposure to narrowband noise centered at 8 kHz, with a duration of 60 min and a sound intensity of 100 dB sound pressure level (SPL), effectively established a reliable tinnitus model